Clinical trials: 2019-nCoV
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza- health-related outcomes of people with COVID-19 or influenza (influenza only included in updated study analyses) the potential effects of…
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT05160636
- Testing
- COVID-19 Vaccine
- Where
- United States
- Volunteers
- 999 people
- Sponsor
- Pfizer
Pharmacokinetics, Safety Issues
Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)
Pharmacokinetics, safety and efficacy study of GP30341, 200 mg capsules (GEROPHARM LLC, Russia) in healthy volunteers and patients with novel coronavirus infection 2019 (COVID-19) with a high risk of adverse outcome
- Conditions
- Pharmacokinetics, Safety Issues, Efficacy
- Trial name
- NCT05648799
- Testing
- GP30341 capsules 200 mg, Standard therapy
- Where
- 5 sites in Russia
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Geropharm
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077969
- Testing
- Famotidine, Celecoxib
- Where
- 15 sites in United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
2019 Novel Coronavirus
The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients
This is a pilot, randomized, single-center, parallel group, open-label controlled study to evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus Standard of Care (SOC) versus SOC alone in…
- Trial name
- NCT04731051
- Testing
- HCQ01, standard of care (SOC) for COVID-19
- Where
- Jordan
- Sponsor
- King Hussein Cancer Center
Coronavirus Disease 2019
Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)
Popular topic:Clinical trials of the consistency and non-inferiority bridging between batches of recombinant new coronavirus vaccine (CHO cells) Research purpose:Main purpose:1)To evaluate the interbatch consistency of…
- Trial name
- NCT05091411
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Acute Respiratory Distress Syndrome
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
The purpose of this study was to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in hospitalized adult patients diagnosed with SARS-COV-19 acute respiratory distress…
- Trial name
- NCT04502433
- Testing
- CUROSURF® (poractant alfa)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 22 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Covid19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
The primary objective of this study is to evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in participants with mild to moderate COVID-19
- Trial name
- NCT04551898
- Testing
- BGB-DXP593
- Where
- 18 sites in United States, Brazil and 2 more
- Volunteers
- 181 people
- Sponsor
- BeiGene
COVID-19, Vaccine Reaction
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
In this phase 1 study, the inactivated virus vaccine National Research Centre (NRC) Vaccine-101 (VACC-101) will be investigated for its safety and immunogenicity in healthy volunteers with the aim of providing effective and safe…
- Conditions
- COVID-19, Vaccine Reaction, Vaccine Adverse Reaction
- Trial name
- NCT05128721
- Testing
- Covi Vax
- Where
- Egypt
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Research Centre, Egypt
Coronavirus
Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection
Outbreak of 2019 Novel Coronavirus infection started in Wuhan and quickly spread to the world. Suspected patients were isolated and treated in our department.
- Trial name
- NCT04279782
- Testing
- Comprehensive treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Novel Coronavirus Pneumonia
NK Cells Treatment for COVID-19
Since december 2019, acute respiratory disease due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. There is no confirmed antivirus therapy for 2019-nCoV infection.
- Trial name
- NCT04280224
- Testing
- NK Cells
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Henan Medical University
Coronavirus Disease 2019, COVID-19
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease
The Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY) study is a pragmatic prospective, open-label, randomised controlled trial.
- Trial name
- CLARITY (NCT04394117)
- Testing
- Angiotensin Receptor Blockers
- Where
- 22 sites in Australia, India
- Volunteers
- 787 people
- Sponsor
- The George Institute
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
COVID-19 Infection
SaRS-Cov-2 Antibodies Following Exposure to Coronavirus Disease 2019 (COVID-19) and/or Vaccination in Nursing Homes
Presence of SaRS-Cov-2 antibodies following exposure to Coronavirus Disease 2019 (COVID-19) and/or vaccination is a major indicator of immunization. Few data exit about serology response in nursing homes (NHs), i.e.
- Trial name
- NCT04964024
- Testing
- SARS-CoV-2 antibodies
- Where
- France
- Volunteers
- 1,293 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID)…
- Trial name
- RESCUE (NCT04511650)
- Testing
- Razuprotafib Subcutaneous Solution
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
COVID-19
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
- Trial name
- NCT04501783
- Testing
- Favipiravir, Standard of care (SOC), standard concomitant therapy
- Where
- 10 sites in Russia
- Volunteers
- 168 people
- Sponsor
- R-Pharm
Covid19
Remotely-conducted Trial of Famotidine vs Placebo for Patients at Home With Coronavirus (COVID) of 2019 (COVID-19)
Kit for reading vital signs (thermometer, wrist blood pressure device, finger oximeter) and with study drug is overnighted to qualified subjects with early symptoms of COVID-19.
- Trial name
- Pepcid4COV19 (NCT04565392)
- Testing
- Famotidine 20 milligram tablet
- Where
- United States
- Sponsor
- drpykessupplements.com
Covid19, Sepsis
Blood Markers for Identifying & Investigating Infection With COVID19 & Sepsis in Children.
Corona Virus Disease or COVID-19 is caused by SARS-CoV-2 virus. There have been reports of serious COVID-19 illness in children. In addition it has been linked to clusters of children presenting with high fevers and inflammation.
- Trial name
- pSeP (NCT04904523)
- Testing
- Diagnostic Test:Blood test
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Cardiff University
COVID-19
Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19
A randomized, 2-period crossover, single-center, open-label study for viral sample collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and surface samplers will be used to assess viral loads…
- Trial name
- NCT04681079
- Testing
- albuterol sulfate (MDI), albuterol sulfate (nebulizer)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Theravance Biopharma
Covid19
COVID-19 Soliris Expanded Access Protocol
This protocol provides participants with COVID-19 access to Soliris.
- Trial name
- NCT04802083
- Testing
- Eculizumab
- Sponsor
- Alexion Pharmaceuticals, Inc.
Covid19
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2 (Gen2) and will be assessed for safety, tolerability…
- Trial name
- COMET-PEAK (NCT04779879)
- Testing
- Sotrovimab (Gen1), Sotrovimab (Gen2)
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 354 people
- Sponsor
- Vir Biotechnology, Inc.